Země: Singapur
Jazyk: angličtina
Zdroj: HSA (Health Sciences Authority)
CHLORAMBUCIL
DCH AURIGA SINGAPORE
L01AA02
2 mg
TABLET, FILM COATED
CHLORAMBUCIL 2 mg
ORAL
Prescription Only
Excella GmbH & Co. KG
ACTIVE
2001-10-11
LEUKERAN™ Chlorambucil QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains 2 mg of the active ingredient chlorambucil. PHARMACEUTICAL FORM Film-coated tablet. CLINICAL PARTICULARS INDICATIONS LEUKERAN is indicated in the treatment of: Hodgkin’s disease; certain forms of non-Hodgkin’s lymphoma; chronic lymphocytic leukaemia; Waldenstrom’s macroglobulinaemia. DOSAGE AND ADMINISTRATION THE RELEVANT LITERATURE SHOULD BE CONSULTED FOR FULL DETAILS OF THE TREATMENT SCHEDULES USED. _LEUKERAN_ is administered orally. • ADULTS _ _ _HODGKIN’S DISEASE_ Used as a single agent in the palliative treatment of advanced disease a typical dosage is 0.2 mg/kg/day for 4 to 8 weeks. _LEUKERAN_ is usually included in combination therapy and a number of regimes have been used. _LEUKERAN_ has been used as an alternative to nitrogen mustard with a reduction in toxicity but similar therapeutic results. _ _ _NON-HODGKIN’S LYMPHOMA _ Used as a single agent the usual dosage is 0.1 to 0.2 mg/kg/day for 4 to 8 weeks initially; maintenance therapy is then given either by a reduced daily dosage or intermittent courses of treatment. _LEUKERAN _is useful in the management of patients with advanced diffuse lymphocytic lymphoma and those who have relapsed after radiotherapy. There is no significant difference in the overall response rate obtained with _LEUKERAN_ as a single agent and combination chemotherapy in patients with advanced non-Hodgkin’s lymphocytic lymphoma. _CHRONIC LYMPHOCYTIC LEUKAEMIA_ Treatment with _LEUKERAN_ is usually started after the patient has developed symptoms or when there is evidence of impaired bone marrow function (but not marrow failure) as indicated by the peripheral blood count. Initially _LEUKERAN_ is given at a dosage of 0.15 mg/kg/day until the total leukocyte count has fallen to 10,000 per microlitre. Treatment may be resumed 4 weeks after the end of the first course and continued at a Přečtěte si celý dokument
LEUKERAN™ Chlorambucil QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains 2 mg of the active ingredient chlorambucil. PHARMACEUTICAL FORM Film-coated tablet. CLINICAL PARTICULARS INDICATIONS LEUKERAN is indicated in the treatment of: Hodgkin’s disease; certain forms of non-Hodgkin’s lymphoma; chronic lymphocytic leukaemia; Waldenstrom’s macroglobulinaemia. DOSAGE AND ADMINISTRATION THE RELEVANT LITERATURE SHOULD BE CONSULTED FOR FULL DETAILS OF THE TREATMENT SCHEDULES USED. _LEUKERAN_ IS AN ACTIVE CYTOTOXIC AGENT FOR USE ONLY UNDER THE DIRECTION OF PHYSICIANS EXPERIENCED IN THE ADMINISTRATION OF SUCH AGENTS. _LEUKERAN _is administered orally and should be taken daily on an empty stomach (at least one hour before meals or three hours after meals). • ADULTS _HODGKIN’S DISEASE_ Used as a single agent in the palliative treatment of advanced disease a typical dosage is 0.2 mg/kg/day for 4 to 8 weeks. _LEUKERAN _is usually included in combination therapy and a number of regimes_ _have been used. _LEUKERAN _has been used as an alternative to nitrogen mustard with a reduction in_ _ toxicity but similar therapeutic results. _NON-HODGKIN’S LYMPHOMA_ Used as a single agent the usual dosage is 0.1 to 0.2 mg/kg/day for 4 to 8 weeks initially; maintenance therapy is then given either by a reduced daily dosage or intermittent courses of treatment. _LEUKERAN _is useful in the management of patients with advanced diffuse_ _ lymphocytic lymphoma and those who have relapsed after radiotherapy. There is no significant difference in the overall response rate obtained with _LEUKERAN _as a single agent and combination chemotherapy in patients with_ _ advanced non-Hodgkin’s lymphocytic lymphoma. _CHRONIC LYMPHOCYTIC LEUKAEMIA_ Treatment with _LEUKERAN_ is usually started after the patient has developed symptoms or when there is evidence of impaired bone marrow function (but not marrow failure) as indicated by the peripheral blood count. Initially _ LEUKERAN_ is given at a dosage of 0.15 mg/kg/day until the tot Přečtěte si celý dokument